# US 9,753,043 B2 · Methods and algorithms for aiding in the detection of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,753,043 B2 - Document ID: US9753043B2 - Status: Granted - Kind: B2 - Application number: 13/718,457 - Filed: 2012-12-18 - Published: 2013-08-01 - Granted: 2017-09-05 - Earliest claimed: 2011-12-18 - Assignees: 20/20 GeneSystems, Inc. - Applicants: 20/20 Genesystems, Inc. - Inventors: Michael Lebowitz; Ronald Shore - Web page: https://patentgrep.com/patent/US9753043B2 ## CPC - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - G01N 2800/50: Determining the risk of developing a disease - G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject. ## Claims ### Claim 1 A method comprising: a) obtaining a sample from a human subject asymptomatic for lung cancer; b) measuring a panel of markers in the sample, wherein at least two of the markers are selected from CEA, CA125, Cyfra 21-1, Pro-GRP, anti-NY-ESO-1, anti-p53, anti-Cyclin E2 and anti-MAPKAPK3; c) determining a multiple of median (MoM) score for each marker; d) summing the MoM score to obtain a composite score for each human subject, quantifying the increased risk for the presence of lung cancer for the human subject as a risk score, wherein the composite score is matched to a risk category of a grouping of stratified human subject populations wherein each risk category comprises a multiplier indicating increased likelihood of having the lung cancer correlated to a range of composite scores as compared to use of a single threshold value, wherein the multiplier is determined from positive predictive scores of retrospective samples; and, e) administering a computerized tomography (CT) scan to the human subject with a quantified increased risk for the presence lung cancer. ### Claim 2 (depends on 1) The method of claim 1, wherein the markers are selected from CEA, CA125, Cyfra 21-1, anti-NY-ESO-1, anti-p53 and anti-MAPKAPK3. ### Claim 3 (depends on 1) The method of claim 1, wherein the sample is blood, blood serum, blood plasma, or some part thereof. ### Claim 4 (depends on 1) The method of claim 1, wherein the grouping of a stratified human subject population, the multiplier indicating increased likelihood of having the cancer and the range of composite scores are determined from retrospective clinical samples of a population. ### Claim 5 (depends on 1) The method of claim 1, wherein the risk category further comprises a risk identifier. ### Claim 6 (depends on 5) The method of claim 5, wherein the risk identifier is selected from low risk, intermediate-low risk, intermediate risk, intermediate-high risk and highest risk. ### Claim 7 (depends on 1) The method of claim 1, wherein calculating the multiplier indicating increased likelihood of having the cancer for each risk category comprises stratifying the human cohort based on retrospective MoM scores and weighting a known prevalence of the cancer in the cohort by a positive predictive score for each stratified population. ### Claim 8 (depends on 1) The method of claim 1, wherein the grouping of a stratified human subject population comprises at least three risk categories wherein the multiplier indicating increased likelihood of having cancer is about 2 or greater. ### Claim 9 (depends on 1) The method of claim 1, wherein the grouping of a stratified human subject population comprises at least two risk categories wherein the multiplier indicating increased likelihood of having cancer is about 5 or greater. ### Claim 10 (depends on 1) The method of claim 1, wherein the human subject is aged 50 years or older and has a history of smoking tobacco. ### Claim 11 (depends on 1) The method of claim 1, further comprising generating a risk categorization table, wherein the panel of markers is measured, a multiple of median (MoM) score for each marker is determined, a composite score is obtained by summing the MoM score; determining a threshold value used to divide the composite scores into risk groups and assigning a multiplier to each group indicating the likelihood of an asymptomatic human subject having a quantified increased risk for the presence of cancer. ### Claim 12 (depends on 11) The method of claim 11, wherein the groups are in a form selected from an electronic table form, a software application, a computer program, and an excel spreadsheet. ### Claim 13 (depends on 1) The method of claim 1, wherein the panel of markers comprise proteins or polypeptides measured in a binding assay. ### Claim 14 (depends on 1) The method of claim 1, wherein the panel of markers comprise proteins or polypeptides measured using a flow cytometer. ### Claim 15 A method comprising: a) obtaining a sample from a human subject asymptomatic for lung cancer, wherein the human subject is at least 50 years of age or older and has a history of smoking tobacco; b) measuring at least two cancer marker in the sample wherein the at least two cancer markers are selected from CEA, CA125, Cyfra 21-1, Pro-GRP, anti-NY-ESO-1, anti-p53, anti-Cyclin E2 and anti-MAPKAPK3; c) determining a multiple of median (MoM) score for each marker measured in the sample; d) summing the MoM score to obtain a composite score for each human subject, quantifying the increased risk for the presence of lung cancer for the human subject as a risk score, wherein the composite score is matched to one of at least three risk categories of a grouping of stratified human subject populations wherein each risk category comprises a multiplier indicating increased likelihood of having the lung cancer correlated to a range of composite scores as compared to use of a single threshold value, wherein the multiplier is determined from positive predictive scores of retrospective samples; and, e) administering a computerized tomography (CT) scan to the human subject with a quantified increased risk for the presence lung cancer. ### Claim 16 (depends on 15) The method of claim 15, wherein the panel of markers is selected from CEA, CA125, Cyfra 21-1, anti-NY-ESO-1, anti-p53 and anti-MAPKAPK3. ### Claim 17 (depends on 15) The method of claim 15, wherein the sample is blood, blood serum, blood plasma, or a component thereof. ### Claim 18 (depends on 15) The method of claim 15, wherein the composite score of the human subject is compared to the composite score of human subjects in at least three risk categories comprising those at high, intermediate, and low risk. ### Claim 19 (depends on 15) The method of claim 15, wherein the composite score of the human subject is compared to the composite score of human subjects in at least five categories comprising those at highest, intermediate high risk, intermediate risk, intermediate low risk, and low risk. ### Claim 20 (depends on 15) The method of claim 15, wherein the risk score is provided to a physician as the human subject's increased risk of having the presence of the cancer relative to a population before testing. ### Claim 21 (depends on 15) The method of claim 15, wherein calculating the multiplier indicating increased likelihood of having the cancer for each risk category comprises stratifying the human cohort based on retrospective MoM scores and weighting a known prevalence of the cancer in the cohort by a positive predictive score for each stratified population. ### Claim 22 (depends on 15) The method of claim 15, wherein the history of smoking tobacco comprises smoking at least one pack of cigarettes per day for 20 years.